News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,826 Results
Type
Article (13808)
Company Profile (101)
Press Release (251917)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88067)
Career Advice (465)
Deals (15344)
Drug Delivery (67)
Drug Development (36611)
Employer Resources (49)
FDA (6299)
Job Trends (6201)
News (150266)
Policy (14053)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (33)
Alliances (23231)
ALS (36)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (41)
Approvals (6335)
Artificial intelligence (107)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (21)
Brain cancer (16)
Breast cancer (79)
Cancer (618)
Cardiovascular disease (72)
Career advice (408)
Career pathing (12)
CAR-T (22)
Cell therapy (88)
Cervical cancer (4)
Clinical research (30934)
Collaboration (345)
Compensation (155)
Complete response letters (17)
COVID-19 (757)
CRISPR (20)
C-suite (124)
Cystic fibrosis (37)
Data (640)
Denatured (15)
Depression (9)
Diabetes (81)
Diagnostics (1319)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (65)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32155)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37532)
Executive appointments (392)
FDA (6723)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (38)
Generative AI (9)
Gene therapy (101)
GLP-1 (349)
Government (1302)
Grass and pollen (3)
Guidances (16)
Healthcare (3566)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (14)
Infectious disease (792)
Inflammatory bowel disease (55)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (47)
Interviews (59)
IPO (5878)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (180)
Leadership (3)
Legal (3434)
Liver cancer (19)
Lung cancer (82)
Lymphoma (55)
Machine learning (1)
Management (16)
Manufacturing (160)
MASH (32)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9674)
Metabolic disorders (262)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (579)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (713)
Now hiring (8)
Obesity (150)
Opinion (119)
Ovarian cancer (21)
Pain (51)
Pancreatic cancer (14)
Parkinson's disease (47)
Partnered (7)
Patents (117)
Patient recruitment (29)
Peanut (10)
People (28963)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8048)
Phase II (13088)
Phase III (11746)
Pipeline (446)
Policy (72)
Postmarket research (1401)
Preclinical (3222)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (168)
Real estate (2637)
Recruiting (17)
Regulatory (10129)
Reports (14)
Research institute (565)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (728)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (26)
The Weekly (30)
United States (7272)
Vaccines (153)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (3)
Date
Today (23)
Last 7 days (214)
Last 30 days (877)
Last 365 days (11747)
2025 (3650)
2024 (12502)
2023 (14250)
2022 (19557)
2021 (20070)
2020 (19034)
2019 (14893)
2018 (11717)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20133)
Australia (2616)
California (1733)
Canada (913)
China (239)
Colorado (70)
Connecticut (68)
Delaware (56)
Europe (39464)
Florida (329)
Georgia (38)
Idaho (9)
Illinois (197)
India (16)
Indiana (135)
Iowa (1)
Japan (93)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (258)
Massachusetts (1498)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (770)
New Mexico (7)
New York (513)
North Carolina (396)
North Dakota (2)
Northern California (713)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (446)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (728)
Tennessee (34)
Texas (233)
Utah (34)
Virginia (75)
Washington D.C. (31)
Washington State (120)
Wisconsin (16)
265,826 Results for "braeburn pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study
Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open.
June 25, 2024
·
12 min read
FDA
Braeburn’s Long-Acting Brixadi Receives FDA Clearance to Treat Opioid Use Disorder
The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.
May 25, 2023
·
3 min read
·
Lisa Munger
Pharm Country
Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD).
May 23, 2023
·
12 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi 1 (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe opioid use disorder to the US Food and Drug Administration (FDA).
June 15, 2021
·
1 min read
Press Releases
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
April 8, 2025
·
4 min read
Business
Altruix Approved to Dispense Brixadi® for Moderate to Severe Opioid Use Disorder
Altruix announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).
August 17, 2023
·
2 min read
1 of 26,583
Next
